Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Blocklisting Interim Review

6 Oct 2014 15:58

RNS Number : 5739T
Hikma Pharmaceuticals Plc
06 October 2014
 



 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

Date: 6 October 2014

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

Period of return

From:

1 April 2014

To:

30 September 2014

Balance of unallotted securities under scheme(s) from previous return:

SOP: 967,900 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 378,360 ordinary shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 0 ordinary shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 38,200 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 356,752 ordinary shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 929,700 ordinary shares of 10 pence

LTIP: 400,050 ordinary shares of 10 pence

MIP: 21,608 ordinary shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

 

 

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

967,900

Blocklisting return 01/04/2014

10/04/2014

0

8,500

959,400

25/04/2014

0

2,500

956,900

23/05/2014

0

1,000

955,900

12/06/2014

0

2,500

953,400

12/06/2014

0

1,700

951,700

21/08/2014

0

6,000

945,700

21/08/2014

0

7,500

938,200

12/09/2014

0

8,500

929,700

Blocklisting return 30/09/2014

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

400,050

Blocklisting return 01/04/2014

30/09/2014

-

-

400,050

Blocklisting return 01/10/2014

 

 

Management Incentive Plan ("MIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2014

-

-

378,360

Blocklisting return 01/04/14

18/05/2014

0

261,480

116,880

12/06/2014

0

11,619

105,261

13/06/2014

0

77,487

27,774

30/06/2014

0

741

27,033

07/08/2014

0

2,856

24,177

22/08/2014

0

794

23,383

04/09/2014

0

300

23,083

12/09/2014

0

1,475

21,608

 Blocklisting return 01/10/14

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRKMMGGDVVGDZM
Date   Source Headline
30th Apr 20207:00 amRNSDirectorate Change
30th Apr 20207:00 amRNSTrading Statement
16th Apr 20203:07 pmRNSDirector/PDMR Shareholding
14th Apr 20202:30 pmRNSBlock listing Interim Review
2nd Apr 20207:00 amRNSAGM Update
31st Mar 20207:00 amRNSHikma's favourable ruling in generic Vascepa®
24th Mar 202010:52 amRNSDirector/PDMR Shareholding
19th Mar 202012:00 pmRNSAnnual Financial Report
28th Feb 202012:27 pmRNSDirector/PDMR Shareholding
28th Feb 202012:26 pmRNSDirector/PDMR Shareholding
28th Feb 202012:23 pmRNSDirector/PDMR Shareholding
27th Feb 20204:40 pmRNSDirector/PDMR Shareholding
27th Feb 20204:35 pmRNSBoard Committee Changes
27th Feb 20207:05 amRNSHikma enters agreement to commercialise Ryaltris™
27th Feb 20207:00 amRNSFinal Results
4th Feb 20202:06 pmRNSTotal Voting Rights
4th Feb 20209:07 amRNSNotice of Results
15th Jan 20209:46 amRNSDirector/PDMR Shareholding
15th Jan 20209:44 amRNSDirector/PDMR Shareholding
9th Jan 20208:00 amRNSHikma announces agreement with Arecor
2nd Jan 202010:56 amRNSTotal Voting Rights
10th Dec 201912:06 pmRNSCivica Rx and Hikma announce shipment of medicines
2nd Dec 20195:12 pmRNSTotal Voting Rights
27th Nov 20197:00 amRNSHikma completes FDA response for generic Advair®
21st Nov 20192:47 pmRNSDirector/PDMR Shareholding
8th Nov 201911:17 amRNSBlock Listing Application
7th Nov 20197:00 amRNSTrading Statement
5th Nov 20199:34 amRNSTotal Voting Rights
4th Oct 20191:36 pmRNSHolding(s) in Company
1st Oct 20193:15 pmRNSBlock listing Interim Review
1st Oct 20193:02 pmRNSTotal Voting Rights
17th Sep 20199:00 amRNSHikma launches prefilled syringes in the US
10th Sep 201910:05 amRNSNotice of Accession of Guarantor
6th Sep 20193:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20195:13 pmRNSTotal Voting Rights
13th Aug 201910:20 amRNSDirector/PDMR Shareholding
9th Aug 20199:00 amRNSHikma expands nasal spray capabilities
9th Aug 20197:00 amRNSHalf-year Report
1st Aug 20193:04 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSHikma and Richter sign agreement for cariprazine
23rd Jul 20199:00 amRNSHikma and Civica Rx sign long-term agreement
8th Jul 20199:00 amRNSNotice of Results
2nd Jul 20195:54 pmRNSTotal Voting Rights
3rd Jun 20194:29 pmRNSTotal Voting Rights
17th May 20194:09 pmRNSResult of AGM
17th May 20193:33 pmRNSDirector/PDMR Shareholding
17th May 20197:00 amRNSTrading Statement
2nd May 20197:00 amRNSTotal Voting Rights
1st May 20199:00 amRNSHikma launches 100th injectable medicine in US
15th Apr 20194:26 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.